PMV Pharmaceuticals, Inc. reported full year 2025 financial results including a net loss of $77.7 million and cash of $112.9 million as of December 31, 2025, providing runway to end of Q2 2027. The company highlighted progress in the PYNNACLE Phase 2 trial for rezatapopt and plans NDA submission in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.
Key takeaways
Cash, cash equivalents, and marketable securities of $112.9 million as of December 31, 2025, providing runway to end of Q2 2027
Net loss of $77.7 million for year ended December 31, 2025 vs $58.7 million in 2024
R&D expenses $69.9 million in 2025 vs $58.5 million in 2024
G&A expenses $16.3 million in 2025 vs $26.9 million in 2024
46% ORR in 48 evaluable ovarian cancer patients (Sep 4, 2025 cutoff) with median duration 8.0 months
FDA Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancer
NDA submission planned for Q1 2027 in platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation